コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 uently associated with an underlying central nervous system disorder.
2 Rabies virus (RV) infection is a fatal nervous system disorder.
3 the adult patients had an underlying central nervous system disorder.
4 search for causes of an inflammatory central nervous system disorder.
5 onutrient underlie several diseases, notably nervous system disorders.
6 role in the pathogenesis of several central nervous system disorders.
7 ion in a variety of animal models of central nervous system disorders.
8 ext of neurobiology and the study of central nervous system disorders.
9 ects of spinal cord injury and other central nervous system disorders.
10 ful transplants for the treatment of central nervous system disorders.
11 as vectors for treating a variety of central nervous system disorders.
12 gical manifestations that overlap with other nervous system disorders.
13 apeutic target for treating numerous central nervous system disorders.
14 to address the increasing burden of central nervous system disorders.
15 controlling pain, obesity, and other central nervous system disorders.
16 rm for silencing genes implicated in central nervous system disorders.
17 ral SOX TFs, and are associated with central nervous system disorders.
18 d for mechanism-based treatments for central nervous system disorders.
19 ve therapeutic potential in multiple central nervous system disorders.
20 he function of sigma(2) receptors in central nervous system disorders.
21 Their dysfunction is associated with many nervous system disorders.
22 enerative medicine aimed at treating central nervous system disorders.
23 ting strictly distinct central or peripheral nervous system disorders.
24 therapeutics and improve symptoms of central nervous system disorders.
25 abinoid metabolism in peripheral and central nervous system disorders.
26 ndidate biomarkers in pwMS and other central nervous system disorders.
27 cancer, inflammatory conditions, and central nervous system disorders.
28 potential for treating GBM and other central nervous system disorders.
29 rm biomarker-based approaches across central nervous system disorders.
30 while there is no recommendation for central nervous system disorders.
31 extensively reported across a wide range of nervous system disorders.
32 target for the treatment of several central nervous system disorders.
33 1-propargyl-4-styrylpiperidines for central nervous system disorders.
34 drug development a reality, particularly for nervous system disorders.
35 se for the treatment of a variety of central nervous system disorders.
36 ant for use in the treatment of many central nervous system disorders.
37 agents in the treatment of multiple central nervous system disorders.
38 ially affecting the onset and/or severity of nervous system disorders.
39 ive therapeutic targets for numerous central nervous system disorders.
40 nt-based remedy to treat psychosis and other nervous system disorders.
41 of cell surface antibody-associated central nervous system disorders.
42 s that can potentially treat various central nervous system disorders.
43 poised to significantly reduce the burden of nervous system disorders.
44 been implicated in a wide variety of central nervous system disorders.
45 of HTR2A and serotonin signaling in central nervous system disorders.
46 to treat pain, drug abuse, and other central nervous system disorders.
47 of drugs for brain tumors and other central nervous system disorders.
48 the heart of efforts to understand and treat nervous system disorders.
49 enetic and pharmacological models of central nervous system disorders.
50 rmacotherapy for addiction and other central nervous system disorders.
51 y reveal white matter pathologies in central nervous system disorders.
52 re to scratch, accompanies numerous skin and nervous system disorders.
53 rapeutic target for the treatment of central nervous system disorders.
54 l therapies for clinically important central nervous system disorders.
55 inhibitors as chromatin-directed therapy for nervous system disorders.
56 ent of pain, inflammation, and other central nervous system disorders.
57 e useful in the treatment of certain central nervous system disorders.
58 a neuroprotective drug for a broad range of nervous system disorders.
59 ociated with 183 disorders, of which 54 were nervous system disorders.
60 tive DRD2 ligands for multiple human central nervous system disorders.
61 e a source of cells for treatment of central nervous system disorders.
62 use in cell replacement therapy for central nervous system disorders.
63 function, and aberrant connectivity leads to nervous system disorders.
65 is a definable, chronic inflammatory central nervous system disorder amenable to immunosuppressive tr
66 verexpressing human APP695 develop a central nervous system disorder and die prematurely, precluding
67 therapy of ischemic stroke and other central nervous system disorders and further support targeting i
69 ocular motility disorders, including central nervous system disorders and peripheral cranial nerve pa
70 y studied target of gene therapy for central nervous system disorders and shares many features with p
71 ial actions may advance our understanding of nervous system disorders and suggest strategies for the
73 in depression, addictions, and other central nervous system disorders and, thus, is an important targ
76 inst atopic asthma, brain injury and central nervous system disorders, as well as several types of ca
77 including cardiovascular disease and central nervous system disorders, as well as various forms of ca
79 peutic potentials of cannabinoids in central nervous system disorders associated with BBB dysfunction
80 r CREB may be a useful strategy for treating nervous system disorders associated with OL excitotoxici
81 argets as well as pathogenesis of peripheral nervous system disorders associated with these viruses a
82 hnique, not only in the diagnosis of central nervous system disorders, but also in the further clinic
83 hallenges and opportunities for ameliorating nervous-system disorders can benefit from both local and
84 ion (EPMR) is an autosomal recessive central nervous system disorder characterized by childhood onset
85 t therapeutic potential for managing central nervous system disorders characterized by dysregulation
86 , cognition and memory disorders, peripheral nervous system disorders, episodic disorders (for exampl
87 tute of Medicine's Forum on Neuroscience and Nervous System Disorders established a "Grand Challenges
88 dverse events, the most common of which were nervous system disorders (four [3%]) and cardiac disorde
89 tute of Medicine's Forum on Neuroscience and Nervous System Disorders has hosted a series of public w
90 eral nutrition (PN), cholestatic disease and nervous system disorders have been associated with high
92 , a recurrent, reversible multifocal central nervous system disorder, high-titer antiphospholipid aut
93 of COMT inhibitors in central and peripheral nervous system disorders; (ii) to provide the history an
97 late this function for treatment of the many nervous system disorders in which altered neurotrophin e
98 plications in the treatment of other central nervous system disorders in which IL-1 activity has been
99 en associated with a number of human central nervous system disorders including autism spectrum disor
101 could be important in the pathophysiology of nervous system disorders including schizophrenia and mig
102 s a promising therapeutic target for central nervous system disorders including schizophrenia and sub
103 s currently under investigation for multiple nervous system disorders, including Alzheimer's disease
104 icacious in the treatment of various central nervous system disorders, including excessive daytime sl
105 iting (ten [2%] patients in each group); and nervous system disorders, including headache (19 [4%] vs
106 erapeutics for the treatment of a variety of nervous system disorders, including pain, anxiety, and P
107 treatment of various central and peripheral nervous system disorders, including Parkinson's disease,
109 -1/Ric-8A complex as a therapeutic target in nervous system disorders, it is necessary to shed light
110 malian nervous systems and effectively treat nervous-system disorders, it is essential to track chang
111 f NMDARs has been implicated in a variety of nervous system disorders, making them attractive therape
112 pathic Gaucher's disease and similar central nervous system disorders may benefit from this treatment
114 gregates associated with several devastating nervous system disorders; mutations in TARDBP, its encod
115 ), failure to thrive (n = 71), other central nervous system disorder (n = 51), head and neck cancer (
116 ular (n = 37; 39.1/100,000 person-years) and nervous system disorders (n = 31; 31.7/100,000 person-ye
118 requent grade 3 or worse adverse events were nervous system disorders, occurring in six (8%) of 80 pa
119 The established belief that the central nervous system disorder of Niemann-Pick type C disease i
120 of relapsing autoimmune inflammatory central nervous system disorders of varying severity that is uni
121 e shown that circulatory system diseases and nervous system disorders often co-occur in patients.
123 ldren with traumatic brain injury or central nervous system disorders or children receiving cancer tr
124 anisms in subgroups of patients with central nervous system disorders, particularly those involving d
125 elopment of novel therapeutic strategies for nervous-system disorders, particularly those related to
126 ical heterogeneity of paraneoplastic central nervous system disorders: Patients with a given clinical
127 that erythropoietin (EPO), a novel agent for nervous system disorders, prevents apoptotic SH-SY5Y cel
128 peutic agents for a diverse array of central nervous system disorders, pursuit of the transport prote
129 s a broad spectrum of central and peripheral nervous system disorders, ranging from microcephaly to h
130 discovery, development, and translation for nervous system disorders still pose many unique challeng
131 s dysfunction has been implicated in central nervous system disorders such as Alzheimer disease.
132 ay be promising for the treatment of central nervous system disorders such as anxiety and depression.
133 maging tools and in the treatment of central nervous system disorders such as depression and sleep ap
135 ing pathways plays a pivotal role in central nervous system disorders, such as Alzheimer's disease (A
136 infection of macaques can result in central nervous system disorders, such as meningitis and encepha
137 ed by the channels are distorted, leading to nervous system disorders, such as seizures and chronic p
138 have recently been clustered with a group of nervous system disorders termed protein misfolding disea
139 Parkinson's disease (PD) is a progressive nervous system disorder that affects movement, whose ear
140 3% of the children had an underlying central nervous system disorder that coincided with the onset of
141 mic control may improve our understanding of nervous system disorders that destabilize breathing, man
142 particularly significant for genetic central nervous system disorders that have begun to achieve Food
143 n isotype III, result in a spectrum of human nervous system disorders that we now call the TUBB3 synd
144 erious treatment-related adverse events were nervous system disorders (three [4%] of 68 patients and
145 As both EO and NPD are heritable central nervous system disorders, we assessed the prevalence of
146 aining in the diagnosis and treatment of the nervous system disorders which are encountered daily.
147 ship between circulatory system diseases and nervous system disorders which can provide context for f
148 yndrome (OMS) is a severe autoimmune central nervous system disorder, which predominantly affects you
149 Stiff-person syndrome is a disabling central nervous system disorder with no satisfactory treatment t
150 r after spinal cord injury and other central nervous system disorders with a demyelinating pathology.
152 in has proregenerative properties in central nervous system disorders, with potentially broad implica